The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

A. P. Toner, F. McLaughlin, F. J. Giles, F. J. Sullivan, E. O'Connell, L. A. Carleton, L. Breen, G. Dunne, A. M. Gorman, J. D. Lewis, S. A. Glynn*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science